About Excellerate Bioscience
Excellerate Bioscience was established in 2016 with a clear mandate: to bring together the best of academic and industrial drug discovery science within a single, agile contract research organisation. Headquartered in the United Kingdom, the company provides molecular and cellular pharmacology services to clients engaged in drug discovery, combining scientific creativity with collaborative working practices.
The company's approach centres on improving the efficiency and translatability of in vitro pharmacological profiling. Its experienced team of drug discovery scientists is organised to deliver both rigour and flexibility, qualities that organisations working at early discovery stages often require from external partners.
Excellerate Bioscience's service portfolio spans several key areas of preclinical research. Capabilities include molecular pharmacology, phenotypic assays, screening and assay development, and work across multiple drug modalities. The company also supports clients through distinct drug discovery phases, with therapeutic area coverage built into its project delivery model. This breadth allows it to serve partners from early target identification through to candidate selection.
With its founding team drawn from both academic and pharmaceutical industry backgrounds, the organisation was built to address a recognised gap: providing high-quality, scientifically innovative pharmacology services with the responsiveness that larger service providers can struggle to match. The mission stated at formation remains central to how the company operates today.
Further information is available at excelleratebio.com.
